Helmholtz Munich
Helmholtz Munich is a publicly funded German biomedical research center within the Helmholtz Association, applying AI, single-cell genomics, optoacoustic imaging, and metabolic disease research to translate discoveries into prevention, diagnostics, and therapeutics for global health challenges.
- Company typePrivate
- Founded1960
- HeadquartersNeuherberg, Germany
- Headcount1,001–5,000
- GTM typeB2B
- OfferingServices
What Helmholtz Munich does
Helmholtz Munich (legal entity: Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH) is a publicly funded German research center and one of 19 institutes in the Helmholtz Association, headquartered in Neuherberg near Munich. Founded in 1960 with 1,001–5,000 employees, the center pursues mechanistic and translational research on environmental health, metabolic disease (diabetes, obesity), cancer, and neurological disorders, operating through six thematic research centers: Diabetes (HDC), Environmental Health (EHC), Molecular Targets and Therapeutics (MTC), Stem Cell, Bioengineering, and Computational Health. Its work spans population cohorts (the 40-year KORA study in Augsburg), single-cell biology (leading the Human Lung Cell Atlas with 2.4 million cells), and clinical imaging modalities (MSOT, RSOM, fast-RSOM, MiROM).
The center's technology stack is anchored in AI and machine learning applied to biomedical imaging, single-cell genomics, and foundation models for health. Proprietary assets include DeepMB (1000x faster optoacoustic reconstruction), MouseMapper (whole-body cellular alteration mapping), RegVelo (gene-regulatory-network + RNA-velocity framework), scPoli (generative single-cell integration), and a portfolio of foundation models for disease pattern recognition. Imaging innovations such as MSOT have been commercialized through the spin-off iThera Medical GmbH, and an experimental GLP-1/GIP/PPAR quintuple agonist is under development for metabolic disease.
The business model is non-commercial: Helmholtz Munich is funded primarily through the German Federal Ministry of Education and Research (BMBF) and state governments as part of the Helmholtz Association, supplemented by competitive grants (ERC, Horizon Europe, DFG) and third-party project funding. There is no disclosed commercial revenue, no pricing model for products, and no traditional go-to-market motion. Instead, the center monetizes impact through peer-reviewed publications, open-access datasets, technology transfer to industry partners, spin-off formation (e.g., iThera Medical), and collaborative research agreements with universities (TUM, Oxford, Tsinghua, UMass Amherst), consortia (Human Cell Atlas, PUREPOLIS), and industry stakeholders.
Helmholtz Munich firmographics
Firmographics- Name
- Helmholtz Munich
- Legal name
- Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
- Website
- https://helmholtz-munich.de
- Company type
- Private
- Founded year
- 1960
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Helmholtz Munich is a publicly funded German biomedical research center within the Helmholtz Association, applying AI, single-cell genomics, optoacoustic imaging, and metabolic disease research to translate discoveries into prevention, diagnostics, and therapeutics for global health challenges.
- Ownership category
- akta.pro rank
Helmholtz Munich industry classification
Industry- Product category
- Biomedical Research Services
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (54171)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
- akta.pro secondary industries
- Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development) (HLAAAIAD), One Health & Zoonotic Disease Partnerships (Human–Animal–Environment) (HLAJAOAJ)
Keywords
Where Helmholtz Munich is headquartered
LocationHeadquarters
- HQ city
- Neuherberg
- HQ country
- Germany
- HQ region
- Europe
Offices1 record
Markets served
Helmholtz Munich business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Others
Distribution channels3 records
Marketing channels4 records
Helmholtz Munich product offering
Product offeringCore offering
Helmholtz Munich is a publicly funded German biomedical research center that conducts fundamental and translational research on environmental health, metabolic diseases (diabetes and obesity), cancer, and neurological disorders. It delivers research outputs including AI foundation models, deep-learning frameworks, optoacoustic imaging technologies, single-cell atlases, and therapeutic candidates, and transfers these to industry via spin-offs and collaborative agreements.
Product overview
Helmholtz Munich is a strategic biomedical research center operating as a multi-disciplinary platform with specialized research centers focused on diabetes and obesity, environmental health, molecular therapeutics, stem cells, bioengineering, and computational health. The portfolio includes AI foundation models for health research, advanced imaging technologies (DeepMB, RSOM, MSOT, fast-RSOM, MiROM), AI-powered analytical frameworks (MouseMapper, RegVelo, scPoli), and comprehensive cell atlases (Human Lung Cell Atlas). The Computational Health Center coordinates Helmholtz AI, a national AI platform. Research centers collaborate through programs like the Helmholtz Biomedical Engineering Initiative, while the Helmholtz Pioneer Campus serves as an innovation hub for biomedical engineering.
Differentiator
Problem solved
Functional benefit
Brands
- Helmholtz Diabetes Center (HDC): Research center focused on diabetes and metabolic diseases, comprising multiple institutes including Adipocytes and Metabolism, Diabetes and Cancer, Diabetes and Endocrinology, Experimental Genetics, and others.
- Environmental Health Center (EHC)
- Computational Health Center
- Stem Cell Center
- Bioengineering Center
- Molecular Targets and Therapeutics Center (MTC)
- Helmholtz Pioneer Campus
- Helmholtz AI
- PUREPOLIS
- Human Lung Cell Atlas
Products and services
- DeepMB A deep-learning framework that reconstructs high-resolution optoacoustic images in real time, approximately 1000x faster than previous methods without compromising image quality; intended for clinical imaging applications.
- MouseMapper (AI Atlas) AI framework using deep learning, fluorescent markers, and light-sheet microscopy to map disease-induced cellular alterations across the entire mouse body at cellular resolution; used for studying diabetes, cancer, neurodegeneration, and autoimmune disorders.
- RegVelo AI-driven computational framework that integrates gene regulatory networks with single-cell RNA velocity to model and predict cellular fate decisions for biomedical researchers.
- fast-RSOM Non-invasive optoacoustic mesoscopy technology that detects early signs of cardiovascular disease by capturing high-resolution images of the smallest blood vessels through the skin at single-capillary resolution.
- MiROM Mid-infrared optoacoustic microscopy enabling label-free visualization of molecular presence in cells and tissues without dyes or markers, for single-cell-level assessment of cancer treatment responses.
- Human Lung Cell Atlas (discovAIR) First holistic single-cell atlas of the human lung integrating 49 datasets from over 100 healthy individuals; serves as a comprehensive reference for understanding lung biology in health and disease.
- scPoli Generative AI model for data integration of high-resolution single-cell datasets, used by researchers to analyze large-scale medical datasets.
- MSOT (Multispectral Optoacoustic Tomography) Scanner Multispectral Optoacoustic Tomography scanner developed by Prof. Vasilis Ntziachristos, utilizing the optoacoustic effect to produce detailed medical images for clinical assessment; commercialized via the iThera Medical GmbH spin-off.
- RSOM (Raster-Scan Optoacoustic Mesoscopy) Raster-Scan Optoacoustic Mesoscopy technology enabling detailed visualization of biological structures within and below the skin, supporting understanding of complex disease processes.
Quantifiable outcome
- MouseMapper identified 31 organ and tissue types with widespread changes in obese mice
- +4 more outcomes
Companies that use Helmholtz Munich
Customer profileSegments4 records
Ideal customer profiles3 records
Helmholtz Munich technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature9 records
Helmholtz Munich partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered major, core and moderate.
- Vector InstitutemajorMOU signed between Vector Institute and Helmholtz Munich's Computational Health Center to strengthen international collaboration in AI and machine learning research. Establishes formal framework for joint research, researcher exchanges, faculty affiliations, and coordinated engagement in bilateral funding programs spanning Canada and Germany.
- iThera Medical GmbHcoreSpin-off company commercializing MSOT (Multispectral Optoacoustic Tomography) technology developed by Prof. Vasilis Ntziachristos at Helmholtz Munich and TUM. The company markets and further develops the technology for clinical applications.
- Technical University of Munich (TUM)coreLong-standing collaboration on multiple research projects including Human Lung Cell Atlas, MSOT development, computational biology, and bioengineering research. TUM is a key academic partner with shared faculty appointments.
- University Hospital AugsburgmajorCollaborative research on environmental health including nighttime heat and stroke risk studies, analyzing 15 years of stroke data from the hospital's neurology department.
- Stowers Institute for Medical ResearchmajorCollaboration on RegVelo AI framework development for predicting cellular fate decisions using zebrafish neural crest as model system.
- University of OxfordmajorAcademic partner in RegVelo AI framework development alongside Stowers Institute and TUM.
- Human Cell Atlas ConsortiumcoreInternational consortium with goal of creating reference maps of all human cells. Helmholtz Munich leads the Human Lung Cell Atlas as founding member.
- University of Massachusetts AmherstmajorLed international study identifying 676 genes causally linked to Type 2 diabetes risk across 7 diabetes-relevant tissues using genetic data from 2.5 million people worldwide.
- Tsinghua UniversitymajorCollaboration on exercise endurance research showing B cells' non-immune role in supporting muscles during exercise.
- PUREPOLIS Consortiummajor€4.9 million Horizon Europe project coordinated by Helmholtz Munich with 19 consortium partners from research, technology, public authorities, and civil society. Core cities: Nantes, Valencia; Follower cities: Berlin, Rybnik, Augsburg.
- Canada-Germany Digital AlliancemoderateBilateral funding program facilitating AI and ML research collaboration between Canada and Germany under the Vector Institute-Helmholtz Munich MOU.
Scale indicators11 records
Recent moves10 records
Expansion highlights5 records
Helmholtz Munich competitors and assessment
Company assessmentMarket position
Strengths5 records
Competitive moat5 records
Key risks5 records
Key highlights6 records
Customer concentration
Helmholtz Munich social profiles
Digital presenceHelmholtz Munich financial estimates
Financial estimateRevenue estimate
Valuation estimate
Helmholtz Munich leadership team
Management profileNumber of profiles
Profiles17 records
Helmholtz Munich funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Helmholtz Munich M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Helmholtz Munich
What does Helmholtz Munich do?
Helmholtz Munich is a publicly funded German biomedical research center that conducts fundamental and translational research on environmental health, metabolic diseases (diabetes and obesity), cancer, and neurological disorders. It delivers research outputs including AI foundation models, deep-learning frameworks, optoacoustic imaging technologies, single-cell atlases, and therapeutic candidates, and transfers these to industry via spin-offs and collaborative agreements.
Is Helmholtz Munich a public or private company?
Helmholtz Munich is a private company. It is classified as state government owned and is currently operating.
When was Helmholtz Munich founded?
Helmholtz Munich was founded in 1960. It employs 1,001 to 5,000 people.
Where is Helmholtz Munich based?
Helmholtz Munich is headquartered in Neuherberg, Germany, in the Europe region.
Does Helmholtz Munich have an API?
No public API is recorded for Helmholtz Munich.
What industry is Helmholtz Munich in?
Helmholtz Munich's product category is Biomedical Research Services. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development). Its NAICS code is 541714 and its SIC code is 8731.